The effectiveness of omalizumab therapy in patients with chronic spontaneous urticaria: the experience of a single-centre study in Poland.

IF 1.4 4区 医学 Q3 ALLERGY
Postepy Dermatologii I Alergologii Pub Date : 2024-06-01 Epub Date: 2024-06-30 DOI:10.5114/ada.2024.141139
Aleksandra Lesiak, Natalia Bień, Klaudia Lipińska, Maria Rajczak, Małgorzata Skibińska, Justyna Ceryn, Dorota Sobolewska-Sztychny, Irmina Olejniczak-Staruch, Joanna Narbutt
{"title":"The effectiveness of omalizumab therapy in patients with chronic spontaneous urticaria: the experience of a single-centre study in Poland.","authors":"Aleksandra Lesiak, Natalia Bień, Klaudia Lipińska, Maria Rajczak, Małgorzata Skibińska, Justyna Ceryn, Dorota Sobolewska-Sztychny, Irmina Olejniczak-Staruch, Joanna Narbutt","doi":"10.5114/ada.2024.141139","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Omalizumab, which is a recombinant, humanised anti-immunoglobulin-E antibody, is the only approved drug for antihistamine refractory chronic spontaneous urticaria (CSU). It has been reported that it is an effective and safe drug, but the data about long-term effectiveness are still lacking.</p><p><strong>Aim: </strong>To perform a retrospective analysis of the patients with CSU treated with omalizumab at the dermatology department to assess effectiveness of omalizumab therapy in the single centre in Poland.</p><p><strong>Material and methods: </strong>A two-and-a-half-year retrospective analysis of patients with CSU undergoing the therapy with omalizumab was conducted. Patients' data were analysed for many factors such as age, gender, severity indexes (UAS7, DLQI), duration and effects of the treatment used.</p><p><strong>Results: </strong>Sixty-one patients with CSU have been treated with omalizumab in the drug program. The number of female patients - 42 (68.9%) significantly dominated over the number of male patients - 19 (31.1%). The mean UAS7 during the first course of treatment declined from 33.2 to 2.8, during the second from 30.9 to 1.7 and during the third 32.7 to 2.5. In case of DLQI the mean scores decrease from 18 to 2.1 in the first cycle, from 16.9 to 1.9 in the second and from 18.6 to 1.1 in the third.</p><p><strong>Conclusions: </strong>Our study confirmed that omalizumab is an effective medicine in a long-term treatment which improves a physical as well as psychological condition of the patients with antihistamine-resistant CSU. To our knowledge, it is the first study in Poland that presents omalizumab effectiveness during three courses of treatment.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253317/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2024.141139","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Omalizumab, which is a recombinant, humanised anti-immunoglobulin-E antibody, is the only approved drug for antihistamine refractory chronic spontaneous urticaria (CSU). It has been reported that it is an effective and safe drug, but the data about long-term effectiveness are still lacking.

Aim: To perform a retrospective analysis of the patients with CSU treated with omalizumab at the dermatology department to assess effectiveness of omalizumab therapy in the single centre in Poland.

Material and methods: A two-and-a-half-year retrospective analysis of patients with CSU undergoing the therapy with omalizumab was conducted. Patients' data were analysed for many factors such as age, gender, severity indexes (UAS7, DLQI), duration and effects of the treatment used.

Results: Sixty-one patients with CSU have been treated with omalizumab in the drug program. The number of female patients - 42 (68.9%) significantly dominated over the number of male patients - 19 (31.1%). The mean UAS7 during the first course of treatment declined from 33.2 to 2.8, during the second from 30.9 to 1.7 and during the third 32.7 to 2.5. In case of DLQI the mean scores decrease from 18 to 2.1 in the first cycle, from 16.9 to 1.9 in the second and from 18.6 to 1.1 in the third.

Conclusions: Our study confirmed that omalizumab is an effective medicine in a long-term treatment which improves a physical as well as psychological condition of the patients with antihistamine-resistant CSU. To our knowledge, it is the first study in Poland that presents omalizumab effectiveness during three courses of treatment.

奥马珠单抗疗法对慢性自发性荨麻疹患者的疗效:波兰单中心研究的经验。
简介奥马珠单抗是一种重组的人源化抗免疫球蛋白-E抗体,是唯一获准用于抗组胺药难治性慢性自发性荨麻疹(CSU)的药物。目的:对皮肤科使用奥马珠单抗治疗的慢性自发性荨麻疹患者进行回顾性分析,以评估波兰单一中心使用奥马珠单抗治疗的有效性:对接受奥马珠单抗治疗的CSU患者进行了为期两年半的回顾性分析。对患者数据的多种因素进行了分析,如年龄、性别、严重程度指数(UAS7、DLQI)、治疗持续时间和效果等:结果:61 名 CSU 患者接受了药物项目中的奥马珠单抗治疗。其中女性患者42人(68.9%),明显多于男性患者19人(31.1%)。第一个疗程的 UAS7 平均值从 33.2 降至 2.8,第二个疗程从 30.9 降至 1.7,第三个疗程从 32.7 降至 2.5。DLQI的平均分在第一周期从18分降至2.1分,第二周期从16.9分降至1.9分,第三周期从18.6分降至1.1分:我们的研究证实,奥马珠单抗是一种长期治疗的有效药物,它能改善抗组胺药物耐药性CSU患者的身体和心理状况。据我们所知,这是波兰第一项介绍奥马珠单抗在三个疗程中疗效的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
7.10%
发文量
107
审稿时长
6-12 weeks
期刊介绍: Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii is a bimonthly aimed at allergologists and dermatologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信